Connect with us

Business

Last Week’s Top Cannabis Stock Winners And May’s Stocks To Watch

Published

on

Medicinal and recreational cannabis continues to spur investment in marijuana-based pharmaceuticals.

Several publicly traded cannabis stocks gained more than 5% this past week, some of which have market capitalizations exceeding $50 million, according to Investopedia. The Solactive North American Medical Marijuana Index, which tracks the medical marijuana sector, gained 1.5% for the week.

Cannabis stocks also trade on other exchanges, such as the New York Stock Exchange, Nasdaq and over the counter.

Following are last week’s five top performers, followed by a list of four cannabis stocks to watch for the month of May.

Insys Therapeutics Inc., Nasdaq: INSY

Insys Therapeutics, a Chandler, Arizona-based specialty pharmaceutical company, was one of the week’s top performers, gaining more than 11%. The stock was boosted by Wednesday’s announcement that the U.S. Food and Drug Administration (FDA) has approved the Syndros product label. Syndros, the company’s lead product, is a liquid, oral dronabinol (synthetic THC) solution for treating nausea that is chemotherapy induced, and for treating anorexia related to AIDS. The approval means the company can now market the product commercially.

Insys Therapeutics, Inc. also markets Subsys, a sublingual fentanyl spray for cancer pain in opioid-tolerant cancer patients in the U.S.

The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for catastrophic epilepsy syndromes in children. It is also developing other products, such as dronabinol line extensions and sublingual spray products.

Insys has posted flat revenues for the last three years, but its operating income fell at the end of 2016 as the company invested more in research. Gross profit has improved over the last three years.

Insys did not post the biggest gain in the past week, but it is the only one of this week’s top five winners that is also listed on Investopedia’s cannabis stocks to watch for March.

Marapharm Ventures Inc., OTC: MRPHF

Marapharm Ventures Inc., a Kelowna, Canada-based medical marijuana company, gained more than 40% this week after the company announced on Tuesday it will apply for a recreational marijuana license in Nevada. The following day, the company received approval for building permits for modular structures. On Thursday, the company announced that Nevada gave final approval to grow and sell cannabis.

Formerly known as Capital Auction Market Inc., the company serves the medical and recreational marijuana industry in Canada and the U.S.

Marapharm applied to Health Canada for a production and sales license three years ago and has passed the necessary security clearances, according to the Daily Marijuana Observer. The application is currently in the screening process. Health Canada advised the company in September it seeks to amend its application to allow for new regulations.

Marapharm’s common shares are traded in Canada under the MDM symbol and in the U.S. and on the Canadian Securities Exchange under the symbol MRPHF on the OTC. In Europe, it trades under the symbol 2M0 on the FSE.

MMJ Phytotech Ltd., ASX: MMJ

MMJ Phytotech Ltd., trading on the Australian Stock Exchange, gained more than 5% for the week, closing at $0.365 AUD Friday. Australia is developing its own medical marijuana program after legalizing it in November of 2016. MMJ is one of several ASX listed cannabis companies.

Shares of Australian companies involved in the production and research of medicinal marijuana have soared more than 130 percent on average in Sydney this year, exceeding the growth rate of peers in the U.S. and Canada by six times, according to Bloomberg. The surge was also sparked by the country easing restrictions on cannabis imports to treat illnesses from cancer to epilepsy.

MMJ Phytotech has focused on becoming a direct supplier to the growing Canadian recreational and medical and markets, which are estimated to have a combined value of C$8 to C$9 billion by 2024.

MMJ holds one of 41 licenses issued by Health Canada.

The company controls operations across the complete medicinal cannabis value chain through three business units.

Tetra Bio-Pharma Inc., OTC: TBPMF

Tetra Bio-Pharma saw shares jump more than 20% for the week. One factor was an agreement signed Wednesday with Panag Pharma to develop and commercialize a pair of cannabinoid based formulations for treating pain and inflammation.

The filing of a patent in ocular disease combined with the patents from Panag in the ocular space indicates strong revenue potential, according to the company.

Tetra Bio-Pharma will have exclusive access to sell the topical and ocular drug in North America with the right of first negotiation outside the U.S. and Canada. The company will also have the right of first negotiation for future cannabinoid-based products.

Tetra Bio-Pharma will work with Panag to ensure a successful development leading to marketing authorization. Panag will continue to focus on the development of new products for unmet medical needs while Tetra will take the lead in commercializing the products.

Zynerba Pharmaceuticals Inc., Nasdaq: ZYNE

Zynerba Pharmaceuticals Inc., another player in the cannabinoid space, finished the week with about a 5% gain.

The company develops and markets synthetic cannabinoid therapeutics for transdermal delivery. The products address the symptoms of patients with fibromyalgia, epilepsy, peripheral neuropathic pain, osteoarthritis and Fragile X syndrome.

Zynerba is developing ZYN001 and ZYN002, the first being a THC pro-drug patch that provides transdermal THC delivery for fibromyalgia and peripheral neuropathic pain, the second being a synthetic CBD gel that provides transdermal, non-psychoactive CBD delivery for osteoarthritis, epilepsy and Fragile X syndrome.

Top four cannabis stocks to watch in May.

1. AbbVie Inc. (ABBV)

AbbVIe is a pharmaceutical company that already has a cannabis-based drug on the market. The FDA approved Marinol, a drug that helps alleviate vomiting or nausea for chemotherapy patients. It also helps AIDS patients who have lost their desire to eat.

ABBV has increased revenues for the past four years. Its operating income has also steadily increased.

AbbVie concentrates almost exclusively on U.S. markets, which represents some degree of risk. Most pharmaceuticals market globally. Should the domestic market falter, ABBV could see a drop in value.

2. Scott’s Miracle-Gro Company, SMG

Known for its lawn and garden products, Scotts Miracle-Gro is developing products for cannabis growers, including pesticides for use on marijuana plants. The products can be used to grow medicinal marijuana.

The stock has experienced a sideways pattern since December 2016. Should the stock find support at its 200-day moving average, recovery is possible.

Revenues surged in the quarter ended April 1, 2017, as did the company’s income. But given the drop in price recently, this could be a stock to watch rather than buy for the time being.

3. Corbus Pharmaceuticals, CRBP

Corbus Pharmaceuticals stock has been up and down over the past year. The company’s marijuana-based drugs are in clinical trials. Resunab, designed to treat sclerosis, has shown promising trials.

The stock tends to dip right before trial results are announced, then rally when results are positive. The company is currently testing Resunab for treating cystic fibrosis. The pessimism/optimism pattern will continue as this drug is tested yet again.

The company has posted negative operating income, with revenues close to zero. It relies on the success of a single drug.

4. Insys Therapeutics Inc. Nasdaq, INSY

Insys Therapeutics is the only one of the cannabis stocks to watch that was listed among last week’s top gainers.

As investors sober up about the marijuana craze, the reality of using it in medicines will set in. Like other sources for drugs, cannabis offers positive prospects and some failures.

The drop in share price for some cannabis stocks indicates the companies have to deliver soon on the promise of medical cannabis.

Investors are advised not to act based on enthusiasm for marijuana, and to pay attention to drug trial results.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...

3.9 stars on average, based on 8 rated postsLester Coleman is a veteran business journalist based in the United States. He has covered the payments industry for several years and is available for writing assignments.




Feedback or Requests?

2 Comments

2 Comments

  1. jolly648

    May 29, 2017 at 4:01 pm

    Lester, what do you think of Aphira and Aurora Cannabis?

  2. Sfinance1966

    June 7, 2017 at 11:10 am

    Are these stock recommendations to be traded within the month or are they also long term holds? Differentiating the trade type would be useful.
    These seem great for inclusion into my pension if they are suitable to hold for the long term.

You must be logged in to post a comment Login

Leave a Reply

Altcoins

Stellar Acquires Blockchain Startup Chain to Form Interstellar

Published

on

The commercial arm of the Stellar Development Corporation has acquired a promising blockchain startup by the name of Chain, paving the way for possibly higher enterprise adoption of distributed ledger technology. The deal adds to Stellar’s credibility as one of the world’s leading blockchain companies.

Chain Acquired

Chain, a San Francisco-based startup pursuing enterprise grade adoption of blockchain technology in finance, has sold to Lightyear in an undisclosed cash agreement. Lightyear, the subsidiary of the Stellar Development Corporation, will be re-named Interstellar, according to official reports. Jed McCaleb, Stellar’s founder, will be the chief technology officer of the newly formed company, which he said should help companies build on the Stellar network. He adds:

“Chain’s team has led the market for enterprise adoption of blockchain technology, which is a critical component of building a future where money and digital assets move over open protocols.”

Interstellar’s new CEO Adam Ludwin explained how the newly merged company will work together:

“Chain has worked from inside the enterprise while Stellar has focused on the network between organizations. As a single team we will have a complete view and set of capabilities to make value-over-IP a reality.”

Chain is said to be a leader in the world of fin-tech, having built enterprise-grade blockchain solutions for Visa, Citigroup and Nasdaq, among others. With the merger, Interstellar will have access to Sequence, Chain’s powerful cloud solution that enables companies to monitor assets moving between private ledgers and the Stellar network.

Previously, Chain had raised more than $43 million across multiple deals. Financiers included Capital One, Citigroup, Pantera Capital and Blockchain Capital.

XLM Price Update

Although the merger between Chain and Lightyear has not had a demonstrably positive effect on XLM’s price, the cryptocurrency continues to outperform leading assets such as Ethereum and bitcoin cash. The XLM price was down 4.4% on Tuesday but has gained 3.2% over the past seven days. By comparison, bitcoin has declined nearly 1% over that period while Cardano has lost more than 10%. Ethereum is trading in positive territory over seven days as prices recovered from 16-month lows.

XLM, which is currently valued at $0.197, has declined roughly 12% over the past month. At current values, it has a market capitalization of $3.7 billion, placing it sixth among active cryptocurrencies. Bitbox is the most active market for XLM traders, accounting for more than 54% of daily transactions.

Disclaimer: The author owns bitcoin, Ethereum and other cryptocurrencies. He holds investment positions in the coins, but does not engage in short-term or day-trading.

Featured image courtesy of Shutterstock.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.6 stars on average, based on 606 rated postsSam Bourgi is Chief Editor to Hacked.com, where he specializes in cryptocurrency, economics and the broader financial markets. Sam has nearly eight years of progressive experience as an analyst, writer and financial market commentator where he has contributed to the world's foremost newscasts.




Feedback or Requests?

Continue Reading

Business

Grayscale’s $6 Million Dollar Bet

Published

on

Grayscale Investments, the company behind the Bitcoin Investment Trust, has announced plans to back a little-known privacy coin by the name of Zen. The news came mere months after Grayscale put Zen on its “conviction list” of potentially high-impact cryptocurrencies.

Zen Investment Trust

On Thursday, Grayscale announced the creation of the Zen Investment Trust, which gives accredited investors direct access to the cryptocurrency. It is the eighth such fund mandated to hold just one currency, joining a list of products that include bitcoin, Ethereum, XRP and Ethereum Classic.

Although the announcement came as a surprise to some crypto observers, Grayscale said the decision was based on intensive research and due diligence.

“Grayscale conducts unparalleled research and due diligence on their investment products, striving to offer regulated and professionally managed exposure to the digital currency market for institutional and accredited investors worldwide,” said Rob Viglione, Grayscale’s founder and president.

According to Fortune, Grayscale has already purchased $6.3 million worth of Zen tokens and plans to increase its holdings in the future.

Grayscale appears to be increasing its exposure to privacy-focused coins, having recently added Zcash to its list of single-currency investment funds. These assets align with Viglione’s vision of financial privacy, which he believes will be a dominant theme in the future.

Zen Token: An Introduction

Horizen, the company behind Zen token, launched in May 2017 as ZenCash before rebranding this past summer. The company has designed a platform that provides users with complete control of their digital footprint, including private chat and development features. Once scaled to full capacity, Horizen’s side-chain technology will allow anyone to develop privacy-focused applications and generate income from them. Sidechains ensure that Horizon has the bandwidth to process large volumes of transactions without running into scalability issues plaguing other cryptocurrencies.

For users, Horizen’s platform is intended to provide end-to-end encryption of their online activity. The company employs zk-SNARKs, a protocol that can prove possession of certain information without revealing that information and without any interaction between the prover and verifier. This protocol is also employed by zCash.

Valued at $82 million, Zen is currently ranked no. 72 by market capitalization, according to latest available data. Zen was down only 1% on Thursday compared with double-digit losses for the broader market. At press time, Zen was valued at $17.16, according to CoinMarketCap. Trade volumes amounted to $1.8 million, with Binance accounting for more than half the daily turnover.

There are currently less than 4.7 million ZEN tokens in circulation out of a total supply of 21 million.

Disclaimer: The author owns bitcoin, Ethereum and other cryptocurrencies. He holds investment positions in the coins, but does not engage in short-term or day-trading.

Featured image courtesy of Shutterstock.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
3 votes, average: 4.67 out of 53 votes, average: 4.67 out of 53 votes, average: 4.67 out of 53 votes, average: 4.67 out of 53 votes, average: 4.67 out of 5 (3 votes, average: 4.67 out of 5)
You need to be a registered member to rate this.
Loading...

4.6 stars on average, based on 606 rated postsSam Bourgi is Chief Editor to Hacked.com, where he specializes in cryptocurrency, economics and the broader financial markets. Sam has nearly eight years of progressive experience as an analyst, writer and financial market commentator where he has contributed to the world's foremost newscasts.




Feedback or Requests?

Continue Reading

Bitcoin

The Anarchist Case For Bitcoin

Published

on

Previously, we have discussed how Bitcoin receives a ton of support from libertarians because of how it works in line with many of their core principles regarding market freedoms. But there are other groups who also share principles with Bitcoin, one of them being anarchists.

Anarchists are known to generally believe in the abolition of all government with force and compulsion being ruled out of the means by which organizations are managed. By extension, crypto-anarchists use software related to Bitcoin to exchange information without affecting their privacy or political freedom.

What Bitcoin Can Do for Anarchism

Bitcoin is essentially the perfect tool to use against corruption, whether in big business or in the government. You have something that is untraceable, impossible to censor or block, and just so happens to cut out a lot of the middlemen. It is basically every beaurocrat’s nightmare.

Many people describe Bitcoin’s protocol as “trustless”, because of how it used an intelligent design to make it technically impossible to rip people off or cheat the system. This takes away the possibility of corruption and creates a world where a certain level of governance is not needed.

Cryptocurrencies are especially attractive to those who have built up a strong disdain for big banks and governments who are mostly net takers. Banks are no longer getting paid, and then there is inability of governments to figure out how to tax these assets. It isn’t easy to track the flow of funds, and sometimes money is put in the system that is never going to come out.

The Politics of Bitcoin

It is important to remember exactly why Bitcoin was invented in the first place. Although we can’t be sure of Satoshi Nakamoto political stances, the fact that he made the string for the first block of Bitcoin contain “The Times 03/Jan/2009 Chancellor on brink of second bailout for banks” is telling. It alludes to the fact that the existing institutions weren’t doing an adequate job of managing the economy.

This brings us to the second point about Bitcoin. No single institution can prop it up, and equally, no single institution can bring it down. It is an inherently populist movement that depends upon grassroots support for its survival. Of course, there are big companies like Coinbase and massive investors involved in the industry, but they don’t directly affect the longevity and function of Bitcoin.

As a standalone protocol, Bitcoin is powerless, but with the backing of a growing number of “evangelical” supporters, it has real potential to change the way business is done. By extension, the political world is going to change as a reaction to the funding and support they receive. It has been said that you can vote at the ballots, or you can vote with your money, and Bitcoin may just be the perfect means by which to put your money behind an ideal.

Granted, this is yet another reason why the price action of Bitcoin is so volatile. It is a “currency” founded on ideals and technology rather than any single economy, and as a result it is only natural that extreme booms and busts occur.

Featured image courtesy of Shutterstock. 

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.1 stars on average, based on 36 rated posts




Feedback or Requests?

Continue Reading

Recent Comments

Recent Posts

A part of CCN

Hacked.com is Neutral and Unbiased

Hacked.com and its team members have pledged to reject any form of advertisement or sponsorships from 3rd parties. We will always be neutral and we strive towards a fully unbiased view on all topics. Whenever an author has a conflicting interest, that should be clearly stated in the post itself with a disclaimer. If you suspect that one of our team members are biased, please notify me immediately at jonas.borchgrevink(at)hacked.com.

Trending